CoChat

The DOI matches its Crossref record; 51 of the 51 references it cites were found in a registry or an index.

Biokinetics and effects of barium sulfate nanoparticles

Open access

Abstract

BACKGROUND: Nanoparticulate barium sulfate has potential novel applications and wide use in the polymer and paint industries. A short-term inhalation study on barium sulfate nanoparticles (BaSO₄ NPs) was previously published [Part Fibre Toxicol 11:16, 2014]. We performed comprehensive biokinetic studies of ¹³¹BaSO₄ NPs administered via different routes and of acute and subchronic pulmonary responses to instilled or inhaled BaSO₄ in rats. METHODS: We compared the tissue distribution of ¹³¹Ba over 28 days after intratracheal (IT) instillation, and over 7 days after gavage and intravenous (IV) injection of ¹³¹BaSO₄. Rats were exposed to 50 mg/m³ BaSO₄ aerosol for 4 or 13 weeks (6 h/day, 5 consecutive days/week), and then gross and histopathologic, blood and bronchoalveolar lavage (BAL) fluid analyses were performed. BAL fluid from instilled rats was also analyzed. RESULTS: Inhaled BaSO₄ NPs showed no toxicity after 4-week exposure, but a slight neutrophil increase in BAL after 13-week exposure was observed. Lung burden of inhaled BaSO₄ NPs after 4-week exposure (0.84 ± 0.18 mg/lung) decreased by 95% over 34 days. Instilled BaSO₄ NPs caused dose-dependent inflammatory responses in the lungs. Instilled BaSO₄ NPs (0.28 mg/lung) was cleared with a half-life of ≈ 9.6 days. Translocated ¹³¹Ba from the lungs was predominantly found in the bone (29%). Only 0.15% of gavaged dose was detected in all organs at 7 days. IV-injected ¹³¹BaSO₄ NPs were predominantly localized in the liver, spleen, lungs and bone at 2 hours, but redistributed from the liver to bone over time. Fecal excretion was the dominant elimination pathway for all three routes of exposure. CONCLUSIONS: Pulmonary exposure to instilled BaSO₄ NPs caused dose-dependent lung injury and inflammation. Four-week and 13-week inhalation exposures to a high concentration (50 mg/m³) of BaSO₄ NPs elicited minimal pulmonary response and no systemic effects. Instilled and inhaled BaSO₄ NPs were cleared quickly yet resulted in higher tissue retention than when ingested. Particle dissolution is a likely mechanism. Injected BaSO₄ NPs localized in the reticuloendothelial organs and redistributed to the bone over time. BaSO₄ NP exhibited lower toxicity and biopersistence in the lungs compared to other poorly soluble NPs such as CeO₂ and TiO₂.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12989-014-0055-3

Cites

51 of 51 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Structural characterization by representative SEM scans of as-produced BaSO 4 nanomaterial and after incubation for testing of persistence. (A) reproduced batch, as-produced powder; (B) NM-220 batch, as-produced powder; (C) pellet of NM-220 after 28d incubation in PBS; (D) pellet of NM-220 after 28d incubation in PSF; (E) pellet of NM-220 after 1d incubation in 0.1 N HCl.
Figure 1 Structural characterization by representative SEM scans of as-produced BaSO 4 nanomaterial and after incubation for testing of persistence. (A) reproduced batch, as-produced powder; (B) NM-220 batch, as-produced powder; (C) pellet of NM-220 after 28d incubation in PBS; (D) pellet of NM-220 after 28d incubation in PSF; (E) pellet of NM-220 after 1d incubation in 0.1 N HCl.CC BY · PubMed Central
Figure 2 Clearance and translocation of 131 BaSO 4 NPs following IT instillation. (A) Lung clearance of 131BaSO4 over time. The clearance half life was approximately 9.6 days. By 28 days, 84% of dose has been cleared from the lungs. (B) Translocated 131Ba from the lungs gradually accumulated in other organs. By 28 days, 29% of the instilled 131Ba dose was retained in the bone and 7% in all the other organs. Data are mean ± standard error of the mean, n = 5 per group.
Figure 2 Clearance and translocation of 131 BaSO 4 NPs following IT instillation. (A) Lung clearance of 131BaSO4 over time. The clearance half life was approximately 9.6 days. By 28 days, 84% of dose has been cleared from the lungs. (B) Translocated 131Ba from the lungs gradually accumulated in other organs. By 28 days, 29% of the instilled 131Ba dose was retained in the bone and 7% in all the other organs. Data are mean ± standard error of the mean, n = 5 per group.CC BY · PubMed Central
Figure 3 Cumulative fecal and urinary excretion of 131 Ba following IT instillation. Elimination of 131Ba was mainly via the feces. By 28 days post-dosing, 30% of the instilled dose was excreted in the feces (A) and only 4.4% in the urine (B). Data are mean ± standard error of the mean, n = 5 per group.
Figure 3 Cumulative fecal and urinary excretion of 131 Ba following IT instillation. Elimination of 131Ba was mainly via the feces. By 28 days post-dosing, 30% of the instilled dose was excreted in the feces (A) and only 4.4% in the urine (B). Data are mean ± standard error of the mean, n = 5 per group.CC BY · PubMed Central
Figure 4 Tissue distribution of 131 Ba following gavage. A. Immediately post-gavage, 100% of dose was recovered in the stomach. B. At 7 days post-gavage, 131Ba was negligible in all tissues. Very low percentages of the dose were detected in bone and bone marrow. Data are mean ± standard error of the mean, n = 5 per group.
Figure 4 Tissue distribution of 131 Ba following gavage. A. Immediately post-gavage, 100% of dose was recovered in the stomach. B. At 7 days post-gavage, 131Ba was negligible in all tissues. Very low percentages of the dose were detected in bone and bone marrow. Data are mean ± standard error of the mean, n = 5 per group.CC BY · PubMed Central
Figure 5 Cumulative fecal and urinary excretion of 131 Ba post-gavage. A. Elimination of 131Ba was nearly 100% via the feces. B. By 7 days post-gavage, only 0.02% of the administered dose was excreted in the urine. Data are mean ± standard error of the mean, n = 5 per group.
Figure 5 Cumulative fecal and urinary excretion of 131 Ba post-gavage. A. Elimination of 131Ba was nearly 100% via the feces. B. By 7 days post-gavage, only 0.02% of the administered dose was excreted in the urine. Data are mean ± standard error of the mean, n = 5 per group.CC BY · PubMed Central
Figure 6 Tissue distribution of 131 Ba post-IV injection. Two hours post-injection, 58% of the injected dose was recovered in the liver and lower percentages in the spleen, bone, bone marrow and the lungs. Over time, 131Ba levels in the liver and lungs decreased with accompanying increases in bone and bone marrow. Data are mean ± standard error of the mean, n = 5 per group. *P <0.05, decrease over time, #P <0.05, increase over time, MANOVA).
Figure 6 Tissue distribution of 131 Ba post-IV injection. Two hours post-injection, 58% of the injected dose was recovered in the liver and lower percentages in the spleen, bone, bone marrow and the lungs. Over time, 131Ba levels in the liver and lungs decreased with accompanying increases in bone and bone marrow. Data are mean ± standard error of the mean, n = 5 per group. *P <0.05, decrease over time, #P <0.05, increase over time, MANOVA).CC BY · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 51 references

Research works printed but not linked: 1

  1. Wohlleben W, Ma-Hock L, Boyko V, Cox G, Egenolf H, Freiberger H, Hinrichsen B, Hirth S, Landsiedel R: Nanospecific guidance in REACH: a comparative physical-chemical characterization of 15 materials with methodical correlations. J Ceram Sci Tech 2013, 4: 93–104.

Cited by

See all 84

Metadata

Authors
Konduru, N., Keller, J., Ma-Hock, L., Gröters, S., Landsiedel, R., Donaghey, T. C., Brain, J. D., Wohlleben, W., & Molina, R. M.
Affiliations
  • Harvard University (US)
  • BASF (Germany) (DE)
Corresponding author
  • Landsiedel, Robert
  • Molina, Ramon M
Venue
Particle and Fibre Toxicology
Published
2014-10-21
Volume
11
Issue
1
Pages
55-55
ISSN
1743-8977 (ISSN-L)
OpenAlex
W2133453275
Cited by
84
References
51
Citations by year
2026: 7 · 2025: 3 · 2024: 7 · 2023: 5 · 2022: 9 · 2021: 6 · 2020: 5 · 2019: 6 · 2018: 11 · 2017: 12 · 2016: 7 · 2015: 6
FWCI
17.63
Type
journal article
Language
en
Open access
Locations
  • Particle and Fibre Toxicology (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • Digital Access to Scholarship at Harvard (DASH) (Harvard University) (submittedVersion, cc-by)
Funders
National Institute of Environmental Health Sciences (ES000002., P30ES000002)
Topics
  • Physical Sciences › Physics and Astronomy › Radiation › Radioactivity and Radon Measurements
  • Physical Sciences › Materials Science › Materials Chemistry › Nanoparticles: synthesis and applications
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Occupational and environmental lung diseases
Keywords
barium sulfate nanoparticles, tissue distribution, lung inflammation, bronchoalveolar lavage, intratracheal instillation, aerosol inhalation, gavage, intravenous injection, nanoparticle clearance, tissue retention, fecal excretion, lung injury, nanoparticle toxicity, rats
MeSH terms
Administration, Oral, Air Pollutants, Animals, Barium Radioisotopes, Barium Sulfate, Dose-Response Relationship, Drug, Female, Half-Life, Injections, Intravenous, Intestinal Absorption, Lung, Male, Pneumonia, Rats, Inbred WKY, Solubility, Tissue Distribution, Inhalation Exposure, Respiratory Mucosa, Toxicity Tests, Acute, Metal Nanoparticles, Toxicity Tests, Subchronic, Respiratory Tract Absorption, Toxicokinetics, Intestinal Elimination

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Biokinetics and effects of barium sulfate nanoparticles. https://app.cochat.ai/papers/10.1186/s12989-014-0055-3
The paper
Konduru, N., Keller, J., Ma-Hock, L., Gröters, S., Landsiedel, R., Donaghey, T. C., Brain, J. D., Wohlleben, W., & Molina, R. M. (2014). Biokinetics and effects of barium sulfate nanoparticles. Particle and Fibre Toxicology. https://doi.org/10.1186/s12989-014-0055-3

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.